关键信息
-
基因名
PAX9
- 应用
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P55771
-
表达区间
Met1~Leu341
-
分子量
40kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
PAX9, a member of the paired box (PAX) gene family, plays a crucial role in various developmental processes, particularly in tooth and craniofacial development. Its involvement in signaling pathways during the early stages of embryogenesis has made it a focal point in studies related to congenital anomalies, such as tooth agenesis, cleft palate, and other craniofacial malformations. The study of PAX9 recombinant protein is essential for understanding its functional mechanisms and the molecular interactions it mediates. Researchers have been focusing on producing PAX9 recombinant proteins to explore their structure and activity, which can provide insights into its role in genetic disorders and developmental biology. Additionally, investigating the binding characteristics of PAX9 with other transcription factors can aid in identifying potential therapeutic targets for conditions arising from its dysfunction. The ongoing research aims to elucidate the importance of post-translational modifications and protein conformational changes in its activity and interaction with DNA, further contributing to the comprehension of craniofacial and dental abnormalities. Understanding PAX9’s biological functions through recombinant protein studies could ultimately lead to advancements in regenerative medicine and gene therapy, offering new avenues for treating patients affected by PAX9-related conditions. This research not only enhances our understanding of developmental biology but also holds potential implications for clinical applications in genetics and developmental medicine.
